I tillæg til mutationerne beskrevet ovenfor, har mutation V32I og I47A været observeret i rebound- isolater med nedsat lopinavir- følsomhed hos protease- hæmmer- erfarne- patienter, som modtog Kaletra- behandling.
In addition to the mutations described above, mutations V32I and I47A have been observed in rebound isolates with reduced lopinavir susceptibility from protease inhibitor experienced patients receiving Kaletra therapy.